Lantheus
LNTH
Market cap $8.03B

115.65 USD

+3.15

2.80%

At close Oct 17, 4:00 PM EDT

After hours

115.65

+0.00

0.00%

1 day

2.80%

5 days

6.49%

1 month

9.58%

3 months

-4.90%

6 months

88.11%

Year to date

83.28%

1 year

57.80%

5 years

511.90%

About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Employees: 834

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

127% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 37

100% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]

41% more call options, than puts

Call options by funds: $109M | Put options by funds: $77.2M

31% more capital invested

Capital invested by funds: $4.19B [Q1] → $5.48B (+$1.29B) [Q2]

12% more funds holding

Funds holding: 402 [Q1] → 449 (+47) [Q2]

0.18% more ownership

Funds ownership: 98.39% [Q1] → 98.57% (+0.18%) [Q2]

1% less repeat investments, than reductions

Existing positions increased: 156 | Existing positions reduced: 157

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$125

8%

upside

Avg. target

$144

24%

upside

High target

$175

51%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Redburn Atlantic Ed Ridley-Day 100% 1-year accuracy 1 / 1 met price target	51%upside $175	Buy Initiated	3 Sept 2024
JMP Securities David Turkaly 45% 1-year accuracy 10 / 22 met price target	8%upside $125	Market Outperform Maintained	1 Aug 2024
Truist Securities Richard Newitter 68% 1-year accuracy 27 / 40 met price target	17%upside $135	Buy Maintained	1 Aug 2024
B. Riley Securities Justin Walsh 44% 1-year accuracy 4 / 9 met price target	26%upside $146	Buy Maintained	25 Jul 2024
Jones Trading Justin Walsh 44% 1-year accuracy 4 / 9 met price target	18%upside $137	Buy Maintained	19 Jul 2024

See Analyst Rankings

Financial journalist opinion

Investors Business Daily

Medical Leader Lantheus Headed Toward Buy Point After Support At Key Level

Lantheus stock is approaching a new buy point on the stock market today after finding support at a key level in recent weeks.

Medical Leader Lantheus Headed Toward Buy Point After Support At Key Level

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus Appoints Julie Eastland as New Board Member

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.

Lantheus Appoints Julie Eastland as New Board Member

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

PYLARIFY is the leading PSMA PET imaging agent, on track to surpass $1 billion in sales by 2024, driving significant revenue growth for Lantheus Holdings, Inc. Lantheus is heavily investing in its oncology and Alzheimer's diagnostics pipeline, positioning itself for substantial long-term growth despite short-term profit impacts. With robust free cash flow, a solid balance sheet, and potential for significant EPS growth, Lantheus Holdings is undervalued and could reach $250 per share by 2028.

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

13 stocks to consider if you're able to brave recession fears

Now that stock investors are beginning to realize that a recession isn't on the way, the U.S. market will get back to doing what is up to before the August swoon: showing strength beyond the Magnificent Seven.

13 stocks to consider if you're able to brave recession fears

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Amanda Morgan - Chief Commercial Officer Conference Call Participants Anthony Petrone - Mizuho Group Roanna Ruiz - Leerink Partners Richard Newitter - Truist Securities Matt Taylor - Jefferies Tara Bancroft - TD Cowen Larry Solow - CJS Securities Yuan Zhi - B. Riley David Turkaly - Citizens JMP Securities LLC Justin Walsh - Jones Trading Andy Hsieh - William Blair Kemp Dolliver - Brookline Capital Markets Richard Newitter - Truist Securities Operator Good morning.

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Lantheus Reports Second Quarter 2024 Financial Results

Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.

Lantheus Reports Second Quarter 2024 Financial Results

10 Stocks That Star Small-Cap Funds Love

Matador Resources and Onto Innovation are widely held stocks among well-regarded small-cap funds.

10 Stocks That Star Small-Cap Funds Love

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday,

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

See News Rankings

Charts implemented using Lightweight Charts™